| | | | | ||||||
| Overview | Overview | Parkinson's and OFF | Calendar & Alerts | Contact | ||||||
| Board of Directors | Financial Information | Privacy Policy | ||||||||
| Senior Management | Corporate Governance | Legal Notice | ||||||||
| Scientific Advisors |
| | | | | ||||||
| Overview | Overview | Parkinson's and OFF | Calendar & Alerts | Contact | ||||||
| Board of Directors | Financial Information | Privacy Policy | ||||||||
| Senior Management | Corporate Governance | Legal Notice | ||||||||
| Scientific Advisors |
Press Releases
|
Press ReleasesMarch 10, 2022 Cynapsus Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended 2015Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its product candidate and corporate activities. March 7, 2022 Cynapsus Therapeutics Provides Company Update at Cowen & Co. 36th Annual Health Care ConferenceCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced that President and CEO, Anthony Giovinazzo, will present a company overview and update today at the Cowen & Co., 36th Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place Hotel at 1:20 p.m. EST in the Vineyard conference room on the 4th Floor. March 1, 2022 Cynapsus to Present at Cowen & Co. 36th Annual Health Care ConferenceCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced that its President and CEO, Anthony Giovinazzo, will present an overview of the Company's PD program and outlook at the Cowen & Co., 36th Annual Health Care Conference. January 13, 2022 Cynapsus Therapeutics to Present at Noble Financial Capital Markets Twelfth Annual Investor ConferenceTORONTO, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) today announced its President and CEO, Anthony Giovinazzo, will present an overview of the Company's Parkinson’s disease (“PD”) program and outlook at the NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 18, 2022 at 12:30 p.m. EST in Room 1. January 7, 2022 Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinson’s Clinical StudyTORONTO, NEW YORK, Jan. 7, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) and The Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) today announced that they are working together to incorporate wearable device technology and “big data” approaches into Cynapsus’ pivotal Phase 3 clinical study of APL-130277, a sublingual (under-the-tongue) formulation of apomorphine to treat (“OFF”) episodes in Parkinson’s disease (“PD”) patients. January 4, 2022 Cynapsus Therapeutics Completes Short-Form Amalgamation with Wholly-Owned SubsidiaryTORONTO – Cynapsus Therapeutics Inc. (“Cynapsus” or the “Company”) (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (“CNS”) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced that, in order to simplify the corporate structure of Cynapsus and to reduce administrative costs, effective January 1, 2016, it has completed a vertical short-form amalgamation pursuant to the Canada Business Corporations Act with its previously wholly-owned subsidiary, Adagio Pharmaceuticals Ltd. (“Adagio”). December 10, 2021 Cynapsus Announces Successful Completion of Bioavailability and Pharmacokinetic Study and Provides Update on European Clinical PlansCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (“CNS”) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced that it has successfully completed the CTH-200 bridging study comparing APL-130277 to subcutaneous apomorphine. In addition, the Company provided an update on European clinical plans. December 8, 2021 Cynapsus Therapeutics Announces Positive Data Presentations at World Congress on Parkinson’s Disease and Related Disorders MeetingCynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (“CNS”) pharmaceutical company developing and preparing to commercialize an easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced the presentation of updated clinical data from the Phase 2 trial of APL-130277 in five poster presentations at the XXI World Congress on Parkinson’s Disease and Related Disorders (“IAPRD”) Meeting in Milan, Italy. November 19, 2021 Cynapsus Therapeutics Expands Senior Leadership TeamCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty CNS pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced the appointment of Kristen Galfetti as Vice President, Investor Relations and Corporate Communications and Eric J. Pappert, MD as Vice President, Global Medical Affairs. November 13, 2021 Cynapsus Therapeutics to Present at Stifel 2015 Healthcare ConferenceCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) today announced it will present an overview of the company's Parkinson’s disease program and outlook at the Stifel 2015 Healthcare Conference at the New York Palace Hotel in New York on Tuesday, November 17, 2021 at 8:00 a.m. EST. November 12, 2021 Cynapsus Reports Third Quarter 2015 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (“CNS”) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced financial results for the three and nine months ended September 30, 2015. September 3, 2021 Cynapsus Therapeutics to Present at Two Upcoming Healthcare ConferencesCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) today announced that its President and CEO, Anthony Giovinazzo, will present a corporate overview at the Rodman & Renshaw 17th Annual Global Investment Conference and the BioCentury 22nd Annual NewsMakers in the Biotech Industry Conference. September 2, 2021 Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Safety Study of APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's DiseaseCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company”) today announced enrollment of the first patient in the CTH-301 clinical trial, a pivotal Phase 3 study to examine the safety and tolerability of APL-130277 for the acute treatment of OFF episodes in patients with Parkinson's disease (PD). CTH-300, a pivotal Phase 3 efficacy study, is also ongoing with data expected from both trials in 2016. August 14, 2021 Cynapsus Therapeutics Reports Second Quarter 2015 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty Central Nervous System (“CNS”) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced financial results for the three and six months ended June 30, 2015. June 29, 2022 Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Efficacy Study Evaluating Sublingual, Film Strip Delivery of Apomorphine to Turn Parkinson’s Disease Patients from the OFF to the ON StateCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company”) today announced enrollment of the first patient in the CTH-300 clinical trial, a pivotal Phase 3 study to examine the efficacy, safety and tolerability of APL-130277 for the acute treatment of OFF episodes in patients with Parkinson's disease (PD). June 25, 2022 Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson's Disease and Movement DisordersCynapsus Therapeutics today announced that it presented data from clinical trials of APL-130277, a sublingual apomorphine thin film under development for the on-demand treatment of OFF episodes associated with Parkinson’s disease (PD). Data from the Company’s CTH-105, CTH-104 and CTH-103 clinical studies, presented at the 19th International Congress of Parkinson's Disease and Movement Disorders (MDS) in San Diego, California, showed APL-130277 significantly improved PD symptoms (as measured by MDS-UPDRS Part III), rapidly turned patients from the OFF to ON state and was generally safe and well tolerated. June 23, 2022 Cynapsus Therapeutics Inc. Closes US$72.5 Million Public Offering of Common Shares in the United StatesCynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company” or “Cynapsus”) announced today that it has completed its previously announced underwritten public offering in the United States (the “Offering”) of 5,175,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of approximately US$72.5 million, including the exercise in full of the underwriters’ option to purchase additional common shares. June 17, 2022 Cynapsus Therapeutics Inc. Announces Pricing of US$63.0 Million Public Offering of Common Shares in the United StatesCynapsus Therapeutics Inc. (TSX:CTH)(OTCQX:CYNAD) (the "Company" or "Cynapsus") announced today the pricing of its underwritten public offering in the United States of 4,500,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of approximately US$63.0 million. June 9, 2022 Cynapsus Therapeutics Inc. Announces Launch of Proposed Public Offering of Common Shares in the United StatesCynapsus Therapeutics Inc. announced today that it is offering to sell 4,500,000 common shares in an underwritten public offering pursuant to a registration statement filed with the U.S. Securities and Exchange Commission. In connection with this offering, Cynapsus expects to grant the underwriters a 30-day option to purchase up to an aggregate of 675,000 additional common shares. June 4, 2022 Cynapsus Therapeutics Announces Issuance of U.S. Patent Providing Broad Coverage for Sublingual ApomorphineCynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, is pleased to announce the grant of U.S. Patent No. 9,044,475, an additional patent in its sublingual apomorphine portfolio. This patent is solely owned by Cynapsus and granted with claims that provide Cynapsus with protection of pharmaceutical dosage forms that combine apomorphine hydrochloride particles with an organic pH neutralizing agent and a permeation enhancer in a sublingual film. This patent is scheduled to expire in June of 2030 and covers Cynapsus’ Parkinson’s product candidate, APL-130277, and related formulations. May 15, 2022 Cynapsus Therapeutics Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share ConsolidationCynapsus Therapeutics Inc. announced today the filing of a registration statement with the US Securities and Exchange Commission relating to a public offering in the United States of its common shares and the filing of an application to list on the NASDAQ Capital Market. May 8, 2022 Cynapsus Therapeutics Reports First Quarter 2015 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty Central Nervous System (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD), today announced financial results for the three months ended March 31, 2015. March 31, 2022 Cynapsus Therapeutics Announces CAD$21 Million Private PlacementCynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, today announced the completion of a private placement (the “Offering”) of 22,039,472 common shares of the Company (the “Common Shares”) for gross proceeds of CAD$20,981,579. March 17, 2022 Cynapsus Therapeutics Reports 2014 Annual ResultsTORONTO (March 17, 2022) – Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, today announced financial results for the year ended December 31, 2014. March 16, 2022 Cynapsus to Host Analyst and Investor Breakfast in New York City on March 18Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, announced that it will host an Analyst and Investor Breakfast featuring presentations by executive management and a clinical key opinion leader on Wednesday, March 18, 2022 at 7:30 a.m. in New York City. March 12, 2022 Cynapsus Therapeutics Appoints Tamar Howson to Board of DirectorsCynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent. March 11, 2022 Cynapsus Therapeutics Provides Clinical and Regulatory UpdateCynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF) today announced that it has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Cynapsus’ APL-130277 drug candidate for the acute rescue of OFF episodes associated with Parkinson’s disease (PD) and has received the final meeting minutes. At the meeting, agreement was reached on the design, duration and size for the Phase 3 program clinical studies, as well as for primary and key secondary endpoints. As a result, Cynapsus plans to initiate a pivotal Phase 3 program evaluating the safety and efficacy of APL-130277 in PD patients in the second quarter of 2015. January 15, 2022 Cynapsus to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity ConferenceCynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced that its President and CEO, Anthony Giovinazzo, will present at the Noble Financial Capital Markets’ Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 19th at 10:00am Eastern Standard Time in Room 1. November 25, 2021 Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange’s Senior Equity MarketCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Friday, November 28, 2014. The Company’s common shares will continue to trade under the symbol “CTH,” with its common shares to cease trading on the TSX Venture Exchange concurrent with the commencement of trading on the TSX. November 19, 2021 Cynapsus Therapeutics Announces Positive Top-Line Results from CTH-105 Phase 2 Study of APL-130277TORONTO – Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company focused on Parkinson’s disease, today announced positive top-line results from its CTH-105 Phase 2 clinical trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s disease. November 18, 2021 Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2021Cynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, announces the Company will report results from its CTH-105 Phase 2 clinical trial of APL-130277 for the treatment of OFF motor symptoms of Parkinson’s disease on Wednesday, November 19, 2021 at 6:00 a.m. November 11, 2021 Cynapsus Therapeutics Reports Third Quarter 2014 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip for the on-demand rescue of OFF motor symptoms of Parkinson’s disease, today announced financial results for the three and nine months ended September 30, 2014. October 14, 2021 Cynapsus Therapeutics’ Phase 2 Drug Candidate for Parkinson’s Chosen as One of the Top Ten Neurology Projects to WatchCynapsus Therapeutics Inc. (CTH: TSX‐V) (OTCQX: CYNAF) today announced that its APL-130277 for Parkinson’s disease was recognized as one of the Top Ten Neurology Projects to Watch by a joint selection committee including Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain. October 7, 2021 Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMCCynapsus Therapeutics (CTH: TSXV) (CYNAF: OTCQX), a specialty pharmaceutical company, today announced Thierry Bilbault, Ph.D., has been named Chief Scientific Officer (CSO) and Executive Vice President of Chemistry, Manufacturing and Controls (CMC). September 19, 2021 Cynapsus Therapeutics Announces Change of AuditorCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF) announces that it has changed its auditor. McGovern, Hurley, Cunningham, LLP (the “Former Auditor”) has resigned at the request of the Company, effective September 18, 2014. The Directors of the Company have appointed Ernst & Young LLP (the “Successor Auditor”) of Toronto, Ontario as auditor for the Company, effective September 19, 2021 until the close of the Company’s next Annual General Meeting. August 13, 2021 Cynapsus Therapeutics Reports Second Quarter 2014 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of “off” motor symptoms of Parkinson’s disease, today announced its results for the three and six months ended June 30, 2014. Unless specified otherwise, all amounts are in Canadian dollars. July 17, 2022 Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United StatesTORONTO, CANADA – Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company focused on Parkinson’s disease, today announced that following communication from the United States Food and Drug Administration (“the FDA”) on July 16, 2014, Phase 2 clinical studies for APL-130277 will commence immediately. Specifically, clinical study CTH-105 will be initiated per the proposal submitted to the FDA under the Company´s Investigational New Drug (IND) application. July 8, 2022 Cynapsus Therapeutics Awarded Second Grant from The Michael J. Fox Foundation for Parkinson’s ResearchCynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX) today announced that it has been awarded a new grant of US$500,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support clinical studies to develop APL-130277, a sublingual thin film strip reformulation of apomorphine. This second MJFF grant will be used to fund the Company’s CTH-105 clinical study. May 20, 2022 Cynapsus Therapeutics Grants Stock OptionsCynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, announced today that the Corporation's Board of Directors granted stock options to acquire 2,256,000 common shares. May 14, 2022 Cynapsus Announces No Buccal Mucosal Irritation in FDA Registration Study of APL-130277 for Parkinson’s DiseaseTORONTO, CANADA – Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, today announced no irritation was observed when testing the APL-130277 sublingual apomorphine formulation in a buccal mucosal irritation model in hamsters, either macroscopically (clinician observation of oral cavity) or microscopically. May 7, 2022 Cynapsus Therapeutics Reports First Quarter 2014 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of “off” motor symptoms of Parkinson’s disease, today announced its results for the three months ended March 31, 2014. April 24, 2022 Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson’s DiseaseCynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. April 15, 2022 Cynapsus Therapeutics Completes $25,000,000 Short Form Prospectus OfferingTORONTO - Cynapsus Therapeutics Inc. (CTH: TSX-V and CYNAF: OTCQX) is pleased to announce that it has completed its previously announced short form prospectus offering (the "Offering") of units ("Units") for the maximum aggregate gross proceeds of $25 million (the "Offering"). April 8, 2022 Cynapsus Therapeutics Files Final Short Form ProspectusTORONTO – Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, announced today that it has filed with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario, its final short form prospectus (the “Prospectus”) in connection with an offering of common shares and warrants of Cynapsus for gross proceeds of $15 million to $25 million (the "Offering"). March 28, 2022 Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, today announced positive interim data from its recently completed healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from “off” episodes. The interim CTH-104 study results indicate that a higher load of drug on the strip does result in a higher amount of drug entering the blood stream. March 28, 2022 Cynapsus Therapeutics Files Preliminary Short Form ProspectusCynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, announced today that it has filed a preliminary short form prospectus (the “Prospectus”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of common shares and warrants of Cynapsus for gross proceeds of $15 million to $25 million (the "Offering"). Final pricing and determination of the number of common shares and warrants to be sold pursuant to the Offering will occur immediately prior to the filing of the final short form prospectus in respect of the Offering. March 27, 2022 Cynapsus Therapeutics Reports 2013 Financial Results and Highlights Key DevelopmentsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of “off” motor symptoms of Parkinson’s disease, today announced its results for the year ended December 31, 2013. February 27, 2022 Cynapsus Therapeutics Announces DTC ApprovalCynapsus Therapeutics Inc. (“Cynapsus” or the “Company”) (TSX-V: CTH) (OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the “DTC”) to facilitate electronic settlement of transfers of its common shares in the United States. February 13, 2022 Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of DirectorsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson’s disease, today announced the appointment of Nan Hutchinson to the Board of Directors. January 23, 2022 Cynapsus Therapeutics Announces Exercise of WarrantsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. January 22, 2022 Cynapsus Announces Resignation of Chief Scientific OfficerCynapsus Therapeutics, Inc. (CTH:TSXV) (CYNAF: OTCQX), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities. January 13, 2022 Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of “OFF” episodes in Parkinson’s disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines. November 21, 2021 Cynapsus Therapeutics Reports Third Quarter 2013 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of “off” motor symptoms of Parkinson’s disease, today announced its results for the nine months ended September 30, 2013. August 22, 2021 Cynapsus Therapeutics Reports Second Quarter 2013 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for “off” motor symptoms of Parkinson’s disease, today announced its results for the six months ended June 30, 2013. July 18, 2022 Cynapsus Therapeutics Begins Trading on the OTCQX Marketplace in the United StatesCynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF) (“Cynapsus” or the “Corporation”) today announced that its common shares have been approved for trading in the United States on the OTCQX marketplace (“OTCQX”). May 30, 2022 Cynapsus Therapeutics to Present at the SeeThruEquity Second Annual Investor Conference on June 4, 2022 at 10:00 AM EDTCynapsus Therapeutics Inc. (TSX VENTURE: CTH), a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for “off” motor symptoms of Parkinson’s disease, announced that Anthony Giovinazzo, President and Chief Executive Officer, is scheduled to present at the SeeThruEquity Second Annual Investor Conference on June 4, 2022 at 10:00 a.m. EDT at The Penn Club in New York City. May 28, 2022 Cynapsus Therapeutics Grants Stock OptionsCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that the Corporation's Board of Directors granted stock options to acquire 25,000 common shares. The stock options were granted to a new director of the Corporation, Tomer Gold, at an exercise price equal to $0.31 per share, and expire 5 years from the date of grant. May 23, 2022 Cynapsus Therapeutics Reports First Quarter 2013 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for “off” motor symptoms of Parkinson’s disease, today announced its results for the three months ended March 31, 2013. May 15, 2022 Cynapsus Publishes White Paper on Apomorphine for ‘Off’ Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only known orally administered (sublingual) formulation of apomorphine, the only drug approved to treat the immobility (“off”) symptoms of Parkinson’s disease, has completed a white paper providing background clinical information on apomorphine. May 9, 2022 Cynapsus Announces Completion of Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced today that it has completed its previously announced offering (the "Offering") under the Company’s short form prospectus dated February 21, 2013, as amended by an amendment dated March 8, 2013. May 9, 2022 Cynapsus Therapeutics Appoints Two New DirectorsCynapsus Therapeutics Inc. (TSX-V: CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that Tomer Gold, the current Vice President, Research & Development of Dexcel Pharma (“Dexcel”), and Ilan Oren, currently Vice President, Business Development at Dexcel, will be joining its Board of Directors effective May 9, 2013. May 1, 2022 Cynapsus Therapeutics Grants Stock OptionsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced today that the Corporation's Board of Directors granted stock options to acquire 1,392,000 common shares. April 26, 2022 Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the fourth quarter and fiscal year ended December 31, 2012. March 21, 2022 Cynapsus Raises Additional $1.3 Million As Part Of Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) is pleased to announce that it has completed a second closing of its short form prospectus offering (the "Offering") of units ("Units") for gross proceeds of $1,309,160 (the “Second Closing”). On March 1, 2013, the Company completed a first closing of the Offering for gross proceeds of $6,008,000 (the “First Closing”). Total gross proceeds from the First Closing and the Second Closing of the Offering are equal to $7,317,160. March 14, 2022 Cynapsus Announces Continuation Of Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it is continuing its previously announced offering (the "Offering") under the Company’s short form prospectus dated February 21, 2022 (the “Prospectus”). March 1, 2022 Cynapsus Therapeutics Completes $6 Million Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) is pleased to announce that it has completed its previously announced short form prospectus offering (the "Offering") of units ("Units") for aggregate gross proceeds of $6,008,000. Concurrent with the closing of the Offering, the Company and the holders of Series A to E debentures agreed to convert $4,031,406 in debt for common shares and warrants. In addition, the Company completed a share consolidation of the Company’s issued and outstanding common shares concurrent on the basis of one (1) new common share for every ten (10) common shares issued and outstanding. February 22, 2022 Cynapsus Therapeutics Files Final Short Form ProspectusCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has received a receipt for its final short form prospectus (the “Prospectus”) which was filed with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of common shares and warrants of Cynapsus for gross proceeds of $6 million to $8 million (the December 11, 2021 Cynapsus Therapeutics Receives Notice of Allowance from United States Patent and Trademark Office (USPTO)Cynapsus Therapeutics Inc. (CTH: TSX-V) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application 13/445,656 with critical claims directed to thin film compositions containing apomorphine formulated for sublingual administration. November 26, 2021 Cynapsus Therapeutics Files Preliminary Short Form ProspectusCynapsus Therapeutics announced today that it has filed a preliminary short form prospectus (the “Prospectus”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of common shares and warrants of Cynapsus for gross proceeds of $6 million to $8 million (the "Offering"). November 23, 2021 Cynapsus Announces Closing of Private PlacementCynapsus Therapeutics Inc., a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that it has closed a brokered private placement (the November 15, 2021 Cynapsus Therapeutics Reports Third Quarter 2012 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) for the rescue of “off” episodes in Parkinson’s disease, today announced its results for the three and nine months ended September 30, 2012. October 29, 2021 Cynapsus Therapeutics’ APL 130277 For Parkinson’s Chosen As One Of The Top Ten Neurology Projects To Watch For 2012Cynapsus Therapeutics Inc. today announced that its APL-130277 for Parkinson’s was recognized as one of the Top Ten Neurology Projects to Watch in 2012 by a joint selection committee including Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain and editor of the highly respected biotechnology publication NeuroPerspective, as well as with Elsevier Business Intelligence, the publishers of In Vivo, Startup and The Pink Sheet. October 24, 2021 Cynapsus Announces Closing of Private PlacementCynapsus Therapeutics Inc. today announced that it has closed a brokered private placement of units. Cynapsus issued an aggregate of 3,400,000 Units at a price of $0.05 per Unit raising gross proceeds of $170,000. October 3, 2021 Cynapsus Therapeutics Signs Term Sheet for C$7 Million OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that it has signed a term sheet with a Health Care / Life Sciences focused Institutional Investment Group (the “Lead Investor”) to be the lead investor in a short form prospectus offering of C$7 million of its common shares and warrants (the “Offering”). August 29, 2021 Cynapsus Therapeutics Reports Second Quarter 2012 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only oral formulation of the only approved drug (apomorphine) for the rescue of “off” episodes in Parkinson’s disease, today announced its results for the three and six months ended June 30, 2012. August 8, 2021 Cynapsus Therapeutics Awarded Grant from The Michael J. Fox FoundationCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that it has been awarded a grant of USD$947,925 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support clinical studies to develop APL-130277, a sublingual (oral) thin film strip reformulation of apomorphine. July 18, 2022 Cynapsus Announces Closing of Private PlacementCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that it has closed a non-brokered private placement (the "Private Placement") of units ("Units"). Cynapsus issued an aggregate of 2,000,000 Units at a price of $0.05 per Unit raising gross proceeds of $100,000. June 13, 2022 Cynapsus Therapeutics Has Article Published in Journal of Commercial BiotechnologyCynapsus Therapeutics (TSX-V: CTH) today announced that an article discussing its APL-130277 drug candidate will be published in the July 2012 Issue of the Journal of Commercial Biotechnology. June 1, 2022 BlueCross BlueShield policy gives boost to CynapsusA recent on-line posting by the Pharmacy and Therapeutic Committee of BlueCross BlueShield of Mississippi indicates that Apokyn (apomorphine hydrochloride) is considered “medically necessary” for patients experiencing hypomobility, or “off” episodes, associated with advanced Parkinson’s disease as determined by a board certified neurologist. May 30, 2022 Cynapsus Therapeutics Reports First Quarter 2012 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the three months ended March 31, 2012. May 17, 2022 Cynapsus Therapeutics Retains US Investor Relations FirmCynapsus Therapeutics Inc. (TSX-V: CTH) today announced that it has retained JSDC, Inc. to provide US-based investor relations services for the Company. May 3, 2022 Cynapsus Therapeutics Nominates New Directors for BoardCynapsus Therapeutics Inc. (“Cynapsus”) (http://www.cynapsus.ca) (TSX-V: CTH) today announced that Dr. Perry Molinoff, the former Vice Provost of the University of Pennsylvania, and Dr. Thomas Picone, a seasoned senior pharma executive, will be nominated to join its Board of Directors. April 23, 2022 Cynapsus Therapeutics appoints Dr. Abraham Lieberman to Clinical Advisory BoardCynapsus Therapeutics, a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that it has appointed Dr. Abraham Lieberman to its Clinical Advisory Board (CAB). April 16, 2022 Cynapsus Provides Update and 2012 OutlookAnthony Giovinazzo, President and CEO of Cynapsus Therapeutics (CTH: TSX-V), has provided shareholders with a strategy update in an open letter that is available on the company web site (www.cynapsus.ca). March 26, 2022 Cynapsus Therapeutics Reports 2011 Financial Results and Highlights Key DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the fourth quarter and fiscal year ended December 31, 2011. March 9, 2022 Cynapsus Therapeutics Announces $1 Million FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a financing (the "Financing") of secured Series E5 Debentures ("Secured Debentures") in the aggregate principal amount of $1,075,865. February 13, 2022 Cynapsus' President and CEO interview to air on Ichannel’s The Next Biggest Winner programCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing a rescue therapy for Parkinson’s disease, today announced that an interview with Anthony Giovinazzo, President and CEO, will air on Ichannel’s The Next Biggest Winner program on Tuesday, February 14th at 7:30 pm. January 10, 2022 Cynapsus Announces Successful Human Volunteer Pilot Proof-of-Concept Results For APL-130277Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company, today announced positive headline data from its recently completed human volunteer pilot proof-of-concept trial for APL 130277, a sublingual thin film strip formulation of apomorphine. December 28, 2021 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a financing (the "Financing") of secured Series E-4 Debentures ("Secured Debentures") in the aggregate principal amount of $229,885. December 22, 2021 Cynapsus Therapeutics Announces Completed Acquisition of Adagio PharmaceuticalsCynapsus Therapeutics Inc. (CTH: TSX-V) announced today the completion of the acquisition of Adagio Pharmaceuticals Ltd. as announced on April 26, 2022 and August 17, 2011. December 15, 2021 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a second closing financing (the December 8, 2021 Neurologist Survey Confirms Need for Improved Administration of Parkinson’s Disease Acute Rescue TherapyCynapsus Therapeutics Inc. (CTH: TSX-V) announced today the results of a large survey of neurologists and movement disorder specialists in the United States, Europe, Japan, China and select countries in the Rest of the World. November 30, 2021 Cynapsus Announces Results of Special Meeting of ShareholdersCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced the results of its Special Meeting of Shareholders held on November 30, 2011. November 23, 2021 Cynapsus Announces Parkinson’s Drug Candidate Progress and Upcoming MilestonesAnthony Giovinazzo, President and CEO of Cynapsus Therapeutics (CTH: TSX-V), has provided shareholders with a strategy update in an open letter that is available on the company web site (www.cynapsus.ca) and below. November 10, 2021 Cynapsus Therapeutics Announces Third Quarter 2011 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the nine months ended September 30, 2011. November 8, 2021 Cynapsus Announces Debenture Financingynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a second closing financing (the "Financing") of secured Series E Debentures ("Secured Debentures") in the aggregate principal amount of $172,414. September 29, 2021 Cynapsus Announces Debenture Financing and Upcoming MilestonesCynapsus Therapeutics Inc. (“Cynapsus” or the “Corporation”) (CTH: TSX-V) announced today that it has arranged financing (the "Financing") of secured Series E Debentures ("Secured Debentures") in the aggregate principal amount of $488,503. August 22, 2021 Cynapsus Therapeutics Announces Second Quarter 2011 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the six months ended June 30, 2011. August 17, 2021 Cynapsus Provides Update on Proposed Acquisition of Adagio Pharmaceuticals and FinancingCynapsus Therapeutics Inc. (the "Corporation" or "Cynapsus") (CTH: TSX-V) announced today that it intends to proceed with the acquisition of Adagio Pharmaceuticals Ltd. ("Adagio") as previously announced on April 26, 2022 (the “Proposed Transaction”) and conduct a Series E Debenture financing. August 15, 2021 IN VIVO: Will New Drugs For Motor Symptoms Of Parkinson's Disease Deliver?Because of the severity of the disease and the unmet medical need, competition to develop more effective treatments for motor complications of Parkinson's disease is fierce. Biopharma companies are employing a variety of strategies including reformulating approved drugs via new delivery systems and developing first-in-class therapies, which although riskier scientifically may command higher prices and greater acceptance from payors. June 24, 2022 Cynapsus Therapeutics Provides Research Update for Parkinson’s Drug CandidateCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today provided an update on the progress of its research activities on its lead drug candidate, APL-130277. June 21, 2022 Cynapsus Provides Update on Brokered Private PlacementCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today provided an update on its previously announced private placement financing (“the Offering”) of its common shares and warrants. June 17, 2022 Cynapsus Therapeutics Announces First Quarter 2011 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the three months ended March 31, 2011. The first quarter of 2011 represents the Company's first reporting period under International Financial Reporting Standards (IFRS). May 31, 2022 Cynapsus Announces Results of Annual and Special Meeting of ShareholdersCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced the results of its Annual and Special Meeting of Shareholders held earlier in the day, on May 31, 2011. May 31, 2022 Cynapsus Therapeutics to Present at BioFinance 2011 ConferenceCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2011 Conference, being held this week in Toronto. May 26, 2022 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged financing of secured Series D Debentures in the aggregate principal amount of $500,000. May 25, 2022 Cynapsus Therapeutics Signs Term Sheet for C$10 Million Private Placement OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that it has signed a term sheet with a Health Care / Life Sciences focused Institutional Investment Group to be the lead investor in a private placement offering of C$10 million of its common shares and warrants. April 26, 2022 Cynapsus Announces Proposed Acquisition of Adagio Pharmaceuticals and Private PlacementCynapsus Therapeutics Inc. (the "Corporation" or "Cynapsus") (CTH: TSX-V) is pleased to announce that it has entered into a preliminary agreement dated April 26, 2022 with Adagio Pharmaceuticals Ltd. ("Adagio") providing for the acquisition by Cynapsus of all of the issued and outstanding shares of Adagio in a share exchange (the "Proposed Transaction"). April 12, 2022 BioWorld Insight: Parkinson’s Update: Disease Pipeline Running the GamutThere were roughly 40 million Americans over the age of 65 in 2010, but as the baby boomer generation continues to reach the monumental age, the number of Americans in that class is expected to increase to 70 million in 2030. April 5, 2022 The Burrill Report: An Interview With Anthony Giovinazzo, President and CEO, Cynapsus TherapeuticsCynapsus Therapeutics is a small Canadian specialty pharma trying to reinvent itself. Under Anthony Giovinazzo, who took the helm at the end of 2009, the company has a new name and new focus. March 23, 2022 BioPharm Insight: Cynapsus seeking CRO for studies of lead PD agent; plans to find global partner post completion of pivotal study - CEOCynapsus Therapeutics (CVE:CTH) is currently engaging in discussions with CROs to help run a Phase I study of lead agent APL-130277, a sublingual formulation of apomorphine, an approved agent used to treat “off-episodes” of patients with advanced Parkinson’s disease (PD), CEO Anthony Giovinazzo said. March 22, 2022 Cynapsus Announces Resignation of Chairman David Pattenden; Rochelle Stenzler Elected as New ChairpersonCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that Rochelle Stenzler, the current Chair of the Corporate Governance and Compensation Committee, was elected to the position of Chairperson. Ms. Stenzler will replace Mr. David Pattenden, who resigned as a director and Chairman for personal reasons. March 7, 2022 Cynapsus Therapeutics Announces Fourth Quarter and Full-Year 2010 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the year ended December 31, 2010. February 18, 2022 Cynapsus Therapeutics to Present at the BIOCOM Global Life Science Partnering ConferenceCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that Anthony J. Giovinazzo, President and Chief Executive Officer, will present at the BIOCOM Global Life Science Partnering Conference at 4:45 P.M. PST, Wednesday, February 23rd, at the Estancia Hotel & Spa in La Jolla, California. February 3, 2022 Cynapsus Announces Closing of Private Placementynapsus Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units") effective February 2, 2011. January 28, 2022 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (“Cynapsus” or the “Corporation”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that it has arranged financing (the "Financing") of secured Series C Debentures ("Secured Debentures") in the aggregate principal amount of $300,000. January 7, 2022 Cynapsus President and CEO Provides Update with Open LetterAnthony Giovinazzo, President and CEO of Cynapsus Therapeutics (CTH: TSX-V), has provided shareholders with a strategy update in an open letter that is available on the company web site (www.cynapsus.ca) and below. January 4, 2022 Cynapsus Announces Signing of Definitive License AgreementCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that on December 31, 2010, it executed a Definitive License Agreement with IntelGenx Corp., its former development partner, whereby IntelGenx agrees to pay a royalty on future sales of the INT0010 (formerly Relivar), a buccal/sublingual formulation of THC (dronabinol) for the symptomatic management of Multiple Sclerosis induced neuropathic pain and other conditions. December 17, 2021 Cynapsus Therapeutics Announces Transfer of Common SharesCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that, effective December 16, 2010, pursuant to the terms of a security purchase agreement dated as of November 15, 2021 among Lorne Gertner and David Hill (collectively, the December 15, 2021 Cynapsus Signs Engagement Letter With Summer Street Research Partners to Provide Financial and Advisory ServicesCynapsus Therapeutics Inc. (CTH: TSX-V) is pleased to announce that it has retained Summer Street Research Partners to provide financial and advisory services. December 2, 2021 Cynapsus Announces Positive Proof of Concept Results in Animals for Parkinson’s Drug CandidateCynapsus Therapeutics Inc. (CTH: TSX-V) is providing today an update on the progress of its research activities on its lead drug candidate, APL 130277, a potential treatment for patients with Parkinson’s disease. November 29, 2021 Cynapsus Announces Signing of Memorandum of UnderstandingCynapsus Therapeutics Inc. (CTH: TSX-V) today announced it has executed a binding Memorandum of Understanding with IntelGenx Corp. November 24, 2021 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has secured financing of a secured Series B debenture in the aggregate amount of $100,000. November 11, 2021 Cynapsus Therapeutics Reports Results for the Nine Months Ended September 30, 2021Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the nine months ended September 30, 2010. November 8, 2021 Cynapsus obtains survey results forecasting favourable acceptance of APL 130277 for Parkinson’s, by US HMOs and InsurersCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that it had received favourable results from a survey conducted by a leading independent healthcare market research group. September 23, 2021 Cynapsus Provides Research Update for Parkinson’s Drug CandidateCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) is providing today an update on the progress of its research activities on its lead drug candidate, APL 130277, a potential treatment for patients with Parkinson’s disease. August 13, 2021 Cynapsus Therapeutics Reports Results for the Six Months Ended June 30, 2022Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the six months ended June 30, 2010. August 5, 2021 Cynapsus Announces Formation of Clinical Advisory Board For Parkinson’s ProgramCynapsus announced today the formation of an international Clinical Advisory Board (“CAB”). The CAB, which is made up of world class knowledge expert physicians, beginning with Dr. Warren Olanow and Dr. Fabrizio Stocchi, will provide counsel and guidance on a range of clinical design and management issues. August 4, 2021 Cynapsus Announces Additional Debenture FinancingCynapsus Therapeutics Inc. announced today that it has completed an additional financing of secured debentures in the aggregate amount of $180,000. July 29, 2022 Cynapsus Announces Addition of Dr. Albert Agro to Parkinson’s Program TeamCynapsus Therapeutics Inc. announced today that it has entered into an agreement with Dr. Albert Agro, an international clinical development expert in CNS diseases. July 27, 2022 Cynapsus Announces Parkinson’s Disease Survey ResultsCynapsus Therapeutics announced today the results of a survey of neurologists and movement disorder specialists relating to Parkinson’s (PD) practices and treatments, specifically targeted at analyzing the use of apomorphine products. July 26, 2022 Cynapsus Announces Signing of License Option Agreement of Parkinson’s Disease TechnologyCynapsus Therapeutics Inc. announced today that it has entered into a License Option Agreement with Adagio Pharmaceuticals Ltd. July 19, 2022 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. announced today that it has secured financing of secured debentures in the aggregate amount of $520,000. June 2, 2022 Cynapsus Amends Terms and Conditions of Brokered Private PlacementCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that the terms and conditions for the previously announced brokered private placement have been amended due to market conditions. May 28, 2022 Cynapsus Therapeutics Reports Results for the Three Months Ended March 31, 2022Cynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the three months ended March 31, 2010. May 7, 2022 Cynapsus Confirms Terms and Conditions of Brokered Private PlacementCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that the terms and conditions for the previously announced brokered private placement will remain as initially set, with each of the units (each a “Unit”) priced at $0.10 per Unit (the “Offering”) for gross proceeds of up to CDN$2,500,000. April 15, 2022 Cannasat Changes Name to Cynapsus TherapeuticsCannasat Therapeutics Inc. (CTH:TSX-V) (“Cannasat”) today announced that it received shareholder approval to change its corporate name to Cynapsus Therapeutics Inc. (“Cynapsus”). The approval was granted at the Annual General Shareholder Meeting held yesterday in Toronto. The Company’s stock symbol will remain as “CTH” on the TSX Venture Exchange. April 7, 2022 Cannasat Therapeutics Announces Private PlacementCannasat Therapeutics Inc. (CTH: TSX-V) today announced it intends to raise gross proceeds of up to CDN$2,500,000 through a brokered private placement of units at a price of $0.10 per Unit. April 6, 2022 Cannasat Therapeutics to Present at BioFinance 2010 ConferenceCannasat Therapeutics (CTH: TSX-V) announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2010 Conference, being held this week in Toronto. March 9, 2022 BioTuesday: Cannasat Batting Hot Streak in its CNS TurnaroundNewly installed in the executive suite at Cannasat Therapeutics (TSX-V:CTH) last November, Mr. Giovinazzo’s mandate is to rebrand the company, founded in 2004 by Moses Znaimer to treat pain with a cannabinoid derivative, into a specialty central nervous system (CNS) drug company. March 5, 2022 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021Cannasat Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the year ended December 31, 2009. March 4, 2022 IntelGenx and Cannasat Announce Letter of Intent for Relivar LicenseIntelGenx Corp. and Cannasat Therapeutics announced today that they have entered into a Letter of Intent (“LOI”). Under the terms of the LOI, IntelGenx would acquire a fifty percent ownership stake from Cannasat and an exclusive worldwide license to develop and commercialize Relivar, a novel formulation of dronabinol. February 4, 2022 Cannasat Announces Signing of Letter of Intent for In-licensing of Parkinson’s Disease TechnologyCannasat Therapeutics, a specialty clinical development pharmaceutical company targeting CNS illness, announced today that it has entered into a Letter of Intent (“LOI”) with Adagio Pharmaceuticals Ltd. granting Cannasat the option to execute a proposed exclusive, worldwide agreement to license all intellectual property relating to APL-130277, a reformulation of an approved Parkinson’s drug. February 1, 2022 Cannasat Update From Anthony Giovinazzo, President & CEOI want to take this opportunity to give you an update on our progress at Cannasat Therapeutics since my appointment as President and CEO on November 16th, 2009. January 11, 2022 Cannasat Therapeutics Strengthens its Board of DirectorsCannasat Therapeutics Inc., a specialty clinical development pharmaceutical company targeting diseases of the brain, announced today that Ron Hosking has joined its Board of Directors as an independent director. December 22, 2021 Cannasat Therapeutics Announces Debt for Shares SettlementCannasat Therapeutics, a specialty clinical development pharmaceutical company targeting diseases of the brain, today announced that it has agreed to settle $185,287 in debt by issuing 1,852,870 common shares at a deemed price of $0.10 per share. November 27, 2021 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2021Cannasat Therapeutics (CTH: TSX-V), a clinical stage pharmaceutical company developing products to treat neurological disorders, today announced its results for the nine months ended September 30, 2009. November 16, 2021 Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir.Cannasat Therapeutics announced today that Anthony J. Giovinazzo has been appointed to succeed David Hill as Chief Executive Officer, and joins the Company as President and Chief Executive Officer. August 31, 2021 Cannasat Therapeutics Completes Prospectus OfferingCannasat Therapeutics is pleased to announce that it has completed a second tranche of its previously announced short form prospectus offering of units. August 31, 2021 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2022Cannasat Therapeutics, a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. August 6, 2021 Cannasat Therapeutics Completes First Tranche of Prospectus OfferingCannasat Therapeutics is pleased to announce that it has completed a first tranche of its previously announced short form prospectus offering of units. June 10, 2022 Cannasat Therapeutics Prices Offering of UnitsCannasat Therapeutics announced today that it has filed a final short form prospectus dated June 10, 2022 in each of the provinces of British Columbia, Alberta and Ontario for its previously announced offering of units. May 29, 2022 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2022Cannasat Therapeutics Inc. (TSXV: CTH), a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the three months ended March 31, 2009. May 25, 2022 Cannasat Therapeutics Announces Favourable Decision from United States Patent and Trademark OfficeCannasat Therapeutics is pleased to announce today that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a U.S. Patent Application which forms the basis for Cannasat’s lead product, Relivar. May 19, 2022 Cannasat Therapeutics Files Preliminary Short Form ProspectusCannasat Therapeutics today announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Ontario, British Columbia and Alberta in connection with a best efforts offering of units, each unit consisting of one common share and one common share purchase warrant. The offering to raise up to $2.5 million will be led by Sandfire Securities Inc. of Toronto. May 15, 2022 Cannasat Therapeutics names Nathan Bryson Chief Scientific OfficerCannasat Therapeutics today announced that Dr. Nathan Bryson, PhD, has been named Chief Scientific Officer, effective May 15, 2009. Dr. Bryson has more than 18 years of experience in pharmaceutical development, holds a BSc in Chemistry from Auburn University, and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (MIT). April 20, 2022 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021TORONTO – Cannasat Therapeutics Inc. (TSXV: CTH), a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the year ended December 31, 2008. April 14, 2022 Cannasat and IntelGenx Announce Positive Phase 1(b) Results: Improved buccal tablet outperforms oral dronabinolCannasat Therapeutics, and its development partner IntelGenx Corp., today announced positive results for the Phase 1(b) clinical trial of Relivar, the first buccal dronabinol drug delivery product, which was developed using IntelGenx’ proprietary AdVersa buccal delivery technology. March 3, 2022 Cannasat Therapeutics Announces Closing of Private PlacementTORONTO – Cannasat Therapeutics Inc. (CTH - TSXV) ("Cannasat") is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units") effective February 27, 2008. February 6, 2022 Cannasat Therapeutics Inc. Announces $600,000 FinancingToronto, Ontario - Cannasat Therapeutics Inc. (CTH : TSXV) announced today that it intends to conduct a non-brokered private placement of up to 6,000,000 Units of Cannasat at a price of $0.10 per Unit, for aggregate gross proceeds of up to $600,000 (the “Offering”). January 28, 2022 Cannasat to Commence Phase 1(b) Study of CAT 310, a Potential Treatment for Neuropathic PainCannasat Therapeutics Inc. ("Cannasat") (TSXV: CTH) and IntelGenx Corp. (OTCBB: IGXT, TSXV: IGX) ("IntelGenx"), announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1(b) clinical study with its lead product, CAT 310. November 27, 2021 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2021Cannasat Therapeutics Inc. (TSXV: CTH), a CNS drug development company, today announced its results for the nine months ended September 30, 2008. August 29, 2021 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2022Cannasat Therapeutics Inc. (TSXV: CTH), a CNS drug development company, today announced its results for the six months ended June 30, 2008. August 12, 2021 Cannasat Therapeutics Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement of units effective August 8, 2008. June 27, 2022 Cannasat Therapeutics Grant of Options and Share IssuanceCannasat Therapeutics Inc. announced today that it has granted options to acquire 1,000,000 shares in the capital of the Corporation effective June 25, 2008. June 23, 2022 Cannasat Therapeutics Receives $1.12 Million from Divesture of Prairie Plant Systems Equity PositionCannasat Therapeutics Inc. announced today that it has reached an agreement to sell the Company’s 12% equity stake in the privately-held, Saskatoon-based Prairie Plant Systems. May 22, 2022 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2022Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the three months ended March 31, 2008. April 10, 2022 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the year ended December 31, 2007. March 18, 2022 Cannasat Therapeutics Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement of units effective March 14, 2008. February 27, 2022 Cannasat Therapeutics Provides Update on Patent Application for Drug Development ProgramsCannasat Therapeutics, the developer of novel cannabinoid-based pharmaceutical products, announced that it has received a favorable decision from the United States Patent and Trademark Office (USPTO). January 14, 2022 Cannasat Therapeutics appoints Dr. Julia Levy to Board of DirectorsCannasat Therapeutics today announced that Dr. Julia Levy has been appointed to its Board of Directors. Dr. Levy is a Canadian pharmaceutical industry leader and brings years of drug discovery, development, and commercialization experience to the Cannasat Board. January 14, 2022 Cannasat Therapeutics appoints Dr. Julia Levy to Board of DirectorsCannasat Therapeutics today announced that Dr. Julia Levy has been appointed to its Board of Directors. Dr. Levy is a Canadian pharmaceutical industry leader and brings years of drug discovery, development, and commercialization experience to the Cannasat Board. December 4, 2021 Cannasat and IntelGenx Complete Phase 1 Study for CAT 310Cannasat Therapeutics announced today the successful completion of its first Phase 1 clinical trial. Results of the randomized, single dose, crossover study comparing two different formulations of the product demonstrated that administration of CAT 310 was safe and well-tolerated with no serious adverse events. November 28, 2021 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2021Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the nine months ended September 30, 2007. November 8, 2021 Cannasat Therapeutics Retains Leading Investor Relations FirmCannasat Therapeutics today announced that it has retained The Equicom Group ("Equicom") to provide the Company with strategic investor relations and financial communications services. October 30, 2021 Cannasat Therapeutics Appoints George Nomikos as Senior Director, Scientific AffairsCannasat Therapeutics today announced that George Nomikos, former Scientific Director at Amgen, Inc. has been appointed as Senior Director, Scientific Affairs. Dr. Nomikos has published more than 140 papers in the field of Neuroscience, Neuropsychopharmacology and Cannabinoid Therapeutics, and brings invaluable knowledge and experience to the Cannasat drug development team. September 17, 2021 Cannasat Therapeutics and IntelGenx Corp. Reach Key MilestoneCannasat Therapeutics Inc., a company specializing in the development of cannabinoid-based pharmaceutical products, announced today the commencement of a Phase 1 clinical study of its lead product, CAT 310, a potential treatment for neuropathic pain. August 28, 2021 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2022Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the six months ended June 30, 2007. August 23, 2021 Cannasat Therapeutics to Commence Phase 1 Study of CAT 310, a Potential Treatment for Neuropathic PainCannasat Therapeutics announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310. June 26, 2022 Cannasat Therapeutics appoints Dr. David Pattenden as Chairman of the BoardCannasat Therapeutics Inc. announced today that Dr. David Pattenden has been appointed Chairman of the Board. May 23, 2022 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2022Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the three months ended March 31, 2007. April 25, 2022 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021Cannasat Therapeutics, the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the year ended December 31, 2006. April 25, 2022 Cannasat Therapeutics Inc. Announces Closing of Private PlacementCannasat Therapeutics is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units"). Cannasat issued an aggregate of 3,790,226 Units at a price of C$0.22 per Unit raising gross proceeds of C$833,849.90. March 20, 2022 Cannasat Therapeutics and IntelGenx enter into agreement to develop cannabinoid-based products for the treatment of mood disorders such as anxiety and depression.Cannasat Therapeutics and IntelGenx today announced a long-term collaborative agreement to co-develop a novel cannabinoid-based product, CAT 320, through a combination of Cannasat’s and IntelGenx’s proprietary drug delivery technologies. December 8, 2021 Cannasat Therapeutics Inc. Grant of Options and Share IssuanceCannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, announced today that it has granted options to acquire 891,240 shares in the capital of the Corporation effective December 4, 2006. December 6, 2021 Cannasat Therapeutics Announces Successful pre-CTA Meeting with Health Canada Regarding CAT 310Cannasat Therapeutics Inc. is pleased to announce a successful pre-CTA (“Clinical Trial Application”) meeting with Health Canada for Phase 1 testing of its lead product, CAT 310, a cannabinoid based pharmaceutical product. November 29, 2021 Cannasat Therapeutics Reports Interim Results For The Nine Months Ended September 30, 2021Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its interim results for the nine-months ended September 30, 2006. November 14, 2021 Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Cannabinoid-based Products Based on Proprietary Drug Delivery TechnologiesCannasat Therapeutics Inc. and IntelGenx Corp. today announced a long-term collaborative agreement to co-develop novel cannabinoid-based products through a combination of Cannasat’s and IntelGenx’s proprietary drug delivery technologies. The collaboration will focus on the development and production of new formulations of cannabinoid pharmaceutical products, starting with Cannasat’s lead product, CAT 310. November 7, 2021 Cannasat Therapeutics Inc. announces NRC-IRAP funding for CAT 210Cannasat Therapeutics Inc. is pleased to announce a contribution agreement with the National Research Council Canada Industrial Research Assistance Program (“NRC-IRAP”) for pre-clinical research and development of CAT 210. CAT 210 is Cannasat’s second product in development that targets the treatment of neuropathic pain with cannabinoids. August 3, 2021 Cannasat Therapeutics Inc. Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed the non-brokered private placement of units previously announced on July 21, 2006. July 21, 2022 Cannasat Therapeutics Inc. Announces New Terms for a Private Placement FinancingCannasat Therapeutics Inc. announced today that due to market conditions it has revised its proposed financing previously announced on June 6, 2006. June 7, 2022 Cannasat Therapeutics Inc. Announces $5.0 Million FinancingCannasat Therapeutics Inc. is pleased to announce that it has entered into an engagement letter concerning a private placement, on a best efforts basis, of up to 15,151,515 Units of Cannasat at a price of C$0.33 per Unit, for aggregate gross proceeds of approximately C$5,000,000. June 5, 2022 Cannasat Therapeutics Inc. Announces New Director and Releases Q1 2006 Financial StatementsCannasat Therapeutics Inc. is pleased to announce the addition of Peter Palframan to the Board of Directors. April 5, 2022 Cannasat Therapeutics now public on the TSX Venture ExchangeMoses Znaimer, Chairman of Cannasat Therapeutics Inc., is pleased to announce that the Company is now a public entity and is trading on the TSX Venture Exchange, under the symbol "CTH" March 22, 2022 Cannasat Therapeutics Inc. and Lonsdale Public Ventures Inc. Announce Completion of Qualifying TransactionCannasat Therapeutics Inc. announced the completion of the amalgamation of Lonsdale and Cannasat Therapeutics Inc. to form a new company with the name "Cannasat Therapeutics Inc." under the provisions of the Business Corporations Act. February 8, 2022 Lonsdale Public Ventures Inc. Announcement Concerning Qualifying Transaction with Cannasat Therapeutics Inc.Lonsdale Public Ventures Inc. announced today further details of its agreement in principle to acquire Cannasat Therapeutics Inc. October 5, 2021 Lonsdale Public Ventures Inc. Announces Letter Of IntentLonsdale Public Ventures Inc., a Capital Pool Company, announces that it has entered into a letter of intent concerning the amalgamation of Lonsdale and Cannasat Therapeutics Inc. |
|
|
| About Cynapsus |  | APL-130277 Product | | Parkinson's Disease | | Investor Relations | | Contact & Legal | | Copyright 2016, Cynapsus Therapeutics Inc. |
Traded on   |